Mission Pharmacal Company recently divested several consumer products to MainPointe Pharmaceuticals. In addition, the marketing rights of additional consumer products have been licensed by Mission to MainPointe. As part of these transactions, the companies have also entered into a renewa-ble Contract Manufacturing Agreement to continue manufacturing all of the included products that are currently made in Mission’s manufacturing facility. These agreements do not involve the marketing or manufacturing of any of Mission’s branded prescription medications.

“These are exciting agreements that will provide consumers greater access to the products in-volved due to MainPointe’s existing relationships within more diverse distribution channels,” said Mission president Neill Walsdorf, Jr. “Mission remains passionate about the products in-volved, and more importantly, we are steadfast in our support of the end users who rely on these products every day.”

As part of the agreements, the following product lines have been divested:

o Thera-Gesic (dual-action, pain relieving creme)
o Thera-Gesic Plus
o Dr. Smith’s Diaper Rash Ointment (pediatrician-developed, diaper rash treatment)
o Dr. Smith’s Diaper Rash Spray
o Dr. Smith’s Adult Barrier Spray (treatment and preventative for incontinence-associated der-matitis)
o Dr. Smith’s Adult Ointment

In addition, marketing rights have been licensed by Mission to MainPointe for the fol-lowing product lines:

o Calcet (calcium supplement option for a broad range of patients)
o Fosfree (calcium, vitamins, and iron supplement)
o Heat Guard (sodium and potassium chloride supplement)
o Maxilube (personal lubricant)
o Lycelle Head Lice Removal Kit (pesticide free, head lice eliminator)